ID: ALA308480

Max Phase: Preclinical

Molecular Formula: C23H24FNO2

Molecular Weight: 365.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1CC(CN2CCC(C(=O)c3ccc(F)cc3)CC2)Cc2ccccc21

Standard InChI:  InChI=1S/C23H24FNO2/c24-20-7-5-17(6-8-20)23(27)18-9-11-25(12-10-18)15-16-13-19-3-1-2-4-21(19)22(26)14-16/h1-8,16,18H,9-15H2

Standard InChI Key:  JFVJCLYJXOVMSI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 365.45

Molecular Weight (Monoisotopic): 365.1791

AlogP: 4.17

#Rotatable Bonds: 4

Polar Surface Area: 37.38

Molecular Species: NEUTRAL

HBA: 3

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.02

CX LogP: 3.89

CX LogD: 3.17

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.76

Np Likeness Score: -0.86

References

1. Cortizo L, Santana L, Ravina E, Orallo F, Fontenla JA, Castro E, Calleja JM, de Ceballos ML..  (1991)  Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogues of butyrophenone.,  34  (7): [PMID:1676759] [10.1021/jm00111a046]

2. Raviña E, Negreira J, Cid J, Masaguer CF, Rosa E, Rivas ME, Fontenla JA, Loza MI, Tristán H, Cadavid MI, Sanz F, Lozoya E, Carotti A, Carrieri A..  (1999)  Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics.,  42  (15): [PMID:10425088] [10.1021/jm981094e]

3. Pastor M, Cruciani G, McLay I, Pickett S, Clementi S..  (2000)  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.,  43  (17): [PMID:10966742] [10.1021/jm000941m]

4. Caro Y, Torrado M, Masaguer CF, Raviña E, Padín F, Brea J, Loza MI..  (2004)  Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics.,  14  (3): [PMID:14741248] [10.1016/j.bmcl.2003.11.064]

5. Caro Y, Torrado M, Masaguer CF, Raviña E, Padín F, Brea J, Loza MI..  (2004)  Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics.,  14  (3): [PMID:14741248] [10.1016/j.bmcl.2003.11.064]

6. Caro Y, Torrado M, Masaguer CF, Raviña E, Padín F, Brea J, Loza MI..  (2004)  Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics.,  14  (3): [PMID:14741248] [10.1016/j.bmcl.2003.11.064]

7. Brea J, Rodrigo J, Carrieri A, Sanz F, Cadavid MI, Enguix MJ, Villazón M, Mengod G, Caro Y, Masaguer CF, Raviña E, Centeno NB, Carotti A, Loza MI..  (2002)  New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.,  45  (1): [PMID:11754579] [10.1021/jm011014y]

8. Loza M, Verde I, Castro M, Orallo F, Fontenla J, Calleja J, Ravina E, Cortizo L, de Ceballos M.  (1991)  5-HT2 antagonist activity of 3-aminomethyltetralones,  1  (12): [10.1016/S0960-894X(01)81054-4]

9. Carro L, Torrado M, Raviña E, Masaguer CF, Lage S, Brea J, Loza MI..  (2014)  Synthesis and biological evaluation of a series of aminoalkyl-tetralones and tetralols as dual dopamine/serotonin ligands.,  71  [PMID:24316025] [10.1016/j.ejmech.2013.10.066]

10. Sheng K, Song Y, Lei F, Zhao W, Fan L, Wu L, Liu Y, Wu S, Zhang Y..  (2022)  Research progress in pharmacological activities and structure-activity relationships of tetralone scaffolds as pharmacophore and fluorescent skeleton.,  227  [PMID:34743062] [10.1016/j.ejmech.2021.113964]

Source

Source(1):

• Scientific Literature